Development of Fluorophore-Labeled Thailanstatin Antibody-Drug Conjugates for Cellular Trafficking Studies.

Bioconjug Chem

Oncology Research Unit, Pfizer Worldwide R&D , Pearl River, New York 10965, United States.

Published: April 2017

AI Article Synopsis

  • The increasing significance of antibody-drug conjugates (ADCs) in cancer treatment necessitates a deeper understanding of their molecular behavior and mechanisms.
  • Imaging studies using traditional fluorophores can distort the ADC's properties, leading to inaccurate assessments of their effectiveness and safety.
  • The introduction of a "clickable" ADC that uses a smaller azide group for labeling provides a more effective alternative, showing better potency and uptake in cells compared to conventional fluorophore-labeled ADCs.

Article Abstract

As the antibody-drug conjugate (ADC) field grows increasingly important for cancer treatment, it is vital for researchers to establish a firm understanding of how ADCs function at the molecular level. To gain insight into ADC uptake, trafficking, and catabolism-processes that are critical to ADC efficacy and toxicity-imaging studies have been performed with fluorophore-labeled conjugates. However, such labels may alter the properties and behavior of the ADC under investigation. As an alternative approach, we present here the development of a "clickable" ADC bearing an azide-functionalized linker-payload (LP) poised for "click" reaction with alkyne fluorophores; the azide group represents a significantly smaller structural perturbation to the LP than most fluorophores. Notably, the clickable ADC shows excellent potency in target-expressing cells, whereas the fluorophore-labeled product ADC suffers from a significant loss of activity, underscoring the impact of the label itself on the payload. Live-cell confocal microscopy reveals robust uptake of the clickable ADC, which reacts selectively in situ with a derivatized fluorescent label. Time-course trafficking studies show greater and more rapid net internalization of the ADCs than the parent antibody. More generally, the application of chemical biology tools to the study of ADCs should improve our understanding of how ADCs are processed in biological systems.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.bioconjchem.6b00718DOI Listing

Publication Analysis

Top Keywords

trafficking studies
8
adc
8
understanding adcs
8
clickable adc
8
development fluorophore-labeled
4
fluorophore-labeled thailanstatin
4
thailanstatin antibody-drug
4
antibody-drug conjugates
4
conjugates cellular
4
cellular trafficking
4

Similar Publications

Background: Transmembrane emp24 trafficking protein 3 (TMED3) is associated with the development of several tumors; however, whether TMED3 regulates the progression of prostate cancer remains unclear.

Materials And Methods: Short hairpin RNA was performed to repress TMED3 in prostate cancer cells (DU145 cells) and in a prostate cancer mice model to determine its function in prostate cancer and .

Results: In the present study, we found that TMED3 was highly expressed in prostate cancer cells.

View Article and Find Full Text PDF

Enhancing leuprolide penetration through enterocytes via the ER-Golgi pathway using lipophilic complexation.

Eur J Pharm Biopharm

December 2024

School of Pharmaceutical Sciences, Beijing Advanced Innovation Center for Structural Biology, and Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, PR China. Electronic address:

Oral delivery of peptide drugs remains one of the most formidable challenges in the frontier of pharmaceutical research. Peptide drugs typically suffer from exceptionally low oral bioavailability, primarily attributed to rigorous enzymatic degradation within the gastrointestinal (GI) tract, limited ability to traverse the enterocyte barrier, and significant first-pass hepatic metabolism. Absorption of peptide drugs via the lymphatic route could potentially bypass intracellular lysosome degradation and hepatic first-pass metabolism.

View Article and Find Full Text PDF

In yeast and mammals, the EXO70 subunit of the exocyst complex plays a key role in mediating the tethering of exocytic vesicles to the plasma membrane (PM). In plants, however, the role of EXO70 in regulating vesicle tethering during exocytosis remains unclear. In land plants, EXO70 has undergone significant evolutionary expansion, resulting in multiple EXO70 paralogues that may allow the exocyst to form various isoforms with specific functions.

View Article and Find Full Text PDF

CAR-T cells are more affected than T lymphocytes by mechanical constraints: A microfluidic-based approach.

Life Sci

December 2024

Department of Mechanical Engineering, University of Zaragoza, Zaragoza, Spain; Instituto de Investigación en Ingeniería de Aragón (I3A), Zaragoza, Spain. Electronic address:

Aims: CAR-T cell therapy has attracted considerable attention in recent years owing to its well-known efficacy against haematopoietic malignancies. Nevertheless, this immunotherapy fails against solid tumours due to hostile conditions found in the tumour microenvironment. In this context, many relevant biochemical factors have been thoroughly studied, but crucial mechanical cues have been underestimated.

View Article and Find Full Text PDF

Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists.

Clin Gastroenterol Hepatol

December 2024

Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA; Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California, USA. Electronic address:

Background And Aims: We sought to ascertain how prior exposure to TNF antagonists impacts treatment response with various classes of advanced therapies in patients with ulcerative colitis (UC), through a systematic review and meta-analysis.

Methods: Through a systematic review of multiple databases through June 30, 2024, we identified 17 RCTs in 8871 adults with moderate-severe UC who were treated with different advanced therapies vs. placebo, and reported efficacy in induction of clinical remission, stratified by prior exposure to TNF antagonists.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!